Elanco(US:ELAN)2026-02-24 14:19Financial Performance - Elanco reported a revenue of $4,715 million for the year ended December 31, 2025, representing a 6% increase from $4,439 million in 2024[227]. - The gross profit for 2025 was $2,593 million, also reflecting a 6% increase compared to $2,436 million in 2024[227]. - Elanco's net loss for 2025 was $232 million, compared to a net income of $338 million in 2024, indicating a substantial decline[227]. - Total revenue for 2025 was $4,715 million, an increase of $276 million or 6% compared to 2024[230]. - Pet Health revenue increased by $157 million, or 7%, to $2,300 million, driven by higher volumes and a 2% increase in pricing[231]. - Farm Animal revenue rose by $112 million, or 5%, to $2,362 million, supported by higher volumes and a 2% increase in pricing, despite a 4% decline due to the divestiture of the aqua business[232]. - Gross profit for 2025 was $2,593 million, a 6% increase from $2,436 million in 2024, with a gross margin of 55.0%[233]. Expenses and Charges - Research and development expenses rose by 7% to $368 million in 2025, up from $344 million in 2024[227]. - Marketing, selling, and administrative expenses rose by $116 million, or 9%, to $1,430 million, also 30% of total revenue[235]. - The company incurred $237 million in asset impairment, restructuring, and other special charges in 2025, a significant increase of 58% from $150 million in 2024[227]. - Asset impairment, restructuring, and other special charges totaled $237 million, a 58% increase from $150 million in 2024, including $155 million related to the 2025 Restructuring Plan[237]. Cash Flow and Investments - Cash provided by operating activities increased by $19 million to $560 million, despite lower net income due to prior year gains from the aqua business divestiture[251]. - Cash used for investing activities in 2025 was $279 million, a decrease from cash provided of $1,158 million in 2024, primarily due to $276 million in net purchases of property and equipment and software, which was $129 million higher than 2024[252]. - Cash used for financing activities in 2025 was $275 million, significantly lower than $1,492 million in 2024, which included $1,600 million in term loan debt repayments[254]. - Capital expenditures in 2025 were $276 million, an increase of $129 million compared to 2024, mainly for the expansion of the monoclonal antibody manufacturing facility and other global projects[256]. Restructuring and Future Plans - The 2025 Restructuring Plan is expected to result in a global headcount reduction of approximately 300 employees and is projected to save about $25 million in 2026 and $60 million in 2027[216]. - The company anticipates capital expenditures in 2026 to be approximately $175 million to $200 million[257]. Goodwill and Impairment - As of December 31, 2025, the net carrying value of goodwill was $4,779 million and other identifiable intangible assets was $3,408 million[132]. - The company recorded a pre-tax goodwill impairment charge of $1,042 million due to increased discount rate assumptions resulting from rising long-term treasury rates[135]. Risks and Challenges - The company is exposed to risks from rising interest rates affecting variable-rate indebtedness, which could increase interest expenses[131]. - The company relies on third parties for products and materials, facing potential disruptions and increased material costs that could adversely affect financial conditions[136]. - The company is exposed to foreign currency exchange rate fluctuations, particularly with the Euro, British pound, and other currencies, which could adversely affect financial results[140]. - Increased regulation or decreased governmental financial support in the farm animal sector could reduce demand for the company's farm animal products[153]. - The company is subject to various state, federal, and international laws and regulations, which are continuously evolving and could impact operations and compliance costs[149]. - Ongoing litigation and regulatory investigations could materially adversely affect the company's reputation and financial condition, with potential significant damages and penalties[157]. - The company is facing a putative securities class action alleging material misstatements regarding the safety and launch timeline of its product Zenrelia, which could lead to further legal challenges[157]. - Unanticipated safety or efficacy concerns, such as the EMA's recommendation to suspend marketing authorization for Kexxtone™, could lead to product recalls and negatively impact sales[169]. - Cybersecurity risks, including potential breaches, could result in unauthorized access to confidential data and disrupt operations, leading to increased costs[173]. - Company faces significant risks related to cyber-attacks, which could lead to substantial costs including increased cybersecurity expenditures and lost revenues from business interruptions[174]. Environmental and Regulatory Compliance - Compliance with complex environmental, health, and safety (EHS) laws is mandatory, with potential liabilities for environmental remediation and fines if regulations are not met[175]. - Company may incur material costs for the investigation and remediation of contaminated land under various environmental laws, impacting financial condition and operations[176]. - Failure to comply with EHS regulations could result in loss of permits and significant remediation costs, adversely affecting business operations[177]. - Stakeholder expectations regarding ESG practices are evolving, and failure to meet these expectations could lead to regulatory fines and reputational damage[180].